Continuous Infusion of Recombinant Factor VIIa: Continue or not?
- 1 January 2001
- journal article
- editorial
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 86 (10) , 942-944
- https://doi.org/10.1055/s-0037-1616514
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrateCurrent Opinion in Hematology, 2000
- Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIaBlood, 2000
- Why do inhibitors arise in patients with haemophilia A?British Journal of Haematology, 1999
- Platelet activity of high‐dose factor VIIa is independent of tissue factorBritish Journal of Haematology, 1997
- Pharmacokinetics and pharmacodynamics of recombinant factor VIIaClinical Pharmacology & Therapeutics, 1994
- The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor.Journal of Clinical Investigation, 1993
- Adjusted dose continuous infusion of factor VIII in patients with haemophilia ABritish Journal of Haematology, 1992
- SUCCESSFUL USE OF RECOMBINANT FACTOR VIIa IN PATIENT WITH SEVERE HAEMOPHILIA A DURING SYNOVECTOMYThe Lancet, 1988